GB202214132D0 - CLL1 binding molecules - Google Patents

CLL1 binding molecules

Info

Publication number
GB202214132D0
GB202214132D0 GBGB2214132.9A GB202214132A GB202214132D0 GB 202214132 D0 GB202214132 D0 GB 202214132D0 GB 202214132 A GB202214132 A GB 202214132A GB 202214132 D0 GB202214132 D0 GB 202214132D0
Authority
GB
United Kingdom
Prior art keywords
binding molecules
cll1
cll1 binding
molecules
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GBGB2214132.9A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Coding Bio Ltd
Original Assignee
Coding Bio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Coding Bio Ltd filed Critical Coding Bio Ltd
Priority to GBGB2214132.9A priority Critical patent/GB202214132D0/en
Publication of GB202214132D0 publication Critical patent/GB202214132D0/en
Priority to PCT/GB2023/052497 priority patent/WO2024069165A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
GBGB2214132.9A 2022-09-27 2022-09-27 CLL1 binding molecules Pending GB202214132D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB2214132.9A GB202214132D0 (en) 2022-09-27 2022-09-27 CLL1 binding molecules
PCT/GB2023/052497 WO2024069165A1 (en) 2022-09-27 2023-09-26 Cll1 binding molecules

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2214132.9A GB202214132D0 (en) 2022-09-27 2022-09-27 CLL1 binding molecules

Publications (1)

Publication Number Publication Date
GB202214132D0 true GB202214132D0 (en) 2022-11-09

Family

ID=83978555

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2214132.9A Pending GB202214132D0 (en) 2022-09-27 2022-09-27 CLL1 binding molecules

Country Status (2)

Country Link
GB (1) GB202214132D0 (en)
WO (1) WO2024069165A1 (en)

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
EP1868650B1 (en) 2005-04-15 2018-10-03 MacroGenics, Inc. Covalent diabodies and uses thereof
US10155816B2 (en) 2005-11-28 2018-12-18 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
KR101799337B1 (en) 2007-06-21 2017-12-20 마크로제닉스, 인크. Covalent diabodies and uses thereof
JP5734201B2 (en) 2008-12-19 2015-06-17 マクロジェニクス，インコーポレーテッド Covalently bonded diabody and use thereof
US9163090B2 (en) 2012-05-07 2015-10-20 Cellerant Therapeutics, Inc. Antibodies specific for CLL-1
US10358492B2 (en) * 2012-09-27 2019-07-23 Merus N.V. Bispecific IgG antibodies as T cell engagers
AU2015292811B2 (en) 2014-07-21 2019-12-19 Novartis Ag Treatment of cancer using a CLL-1 chimeric antigen receptor
CN107108738A (en) * 2014-07-25 2017-08-29 西托姆克斯治疗公司 Anti-cd 3 antibodies, it anti-cd 3 antibodies, polyspecific anti-cd 3 antibodies, polyspecific can be activated can activate anti-cd 3 antibodies and its application method
EP3693391A1 (en) * 2014-09-12 2020-08-12 Genentech, Inc. Anti-cll-1 antibodies and immunoconjugates
CN109641008B (en) 2016-04-01 2021-03-23 凯德药业股份有限公司 Chimeric receptors and methods and uses thereof
WO2020083406A1 (en) * 2018-10-26 2020-04-30 科济生物医药（上海）有限公司 Cll1-targeting antibody and application thereof
CN115697402A (en) * 2020-05-06 2023-02-03 蜻蜓疗法股份有限公司 Antibodies targeting CLEC12A and uses thereof
CN113234169B (en) * 2020-12-11 2022-11-01 广州百暨基因科技有限公司 Targeting CLL1 chimeric antigen receptor and application thereof
US20240067955A1 (en) 2021-01-20 2024-02-29 Coding Bio Limited Methods for high throughput screening of chimeric antigen receptors

Also Published As

Publication number Publication date
WO2024069165A1 (en) 2024-04-04

Similar Documents

Publication Publication Date Title
GB201901306D0 (en) Multi-domain binding molecules
IL289867A (en) Immunostimulatory multimeric binding molecules
GB202020154D0 (en) ROR1-specific variant antigen binding molecules
IL284664A (en) Multispecific binding proteins
IL287555A (en) Binding molecules
IL292698A (en) N-terminal scfv multispecific binding molecules
GB201811408D0 (en) CD137 Binding Molecules
SG11202109535SA (en) Cd3 binding molecules
GB201901305D0 (en) Specific binding molecules
GB202214132D0 (en) CLL1 binding molecules
GB202010329D0 (en) Specific binding molecules
IL288561A (en) Anti-gal9 immune-inhibiting binding molecules
IL308394A (en) Bispecific binding molecule
IL288562A (en) Activating anti-gal9 binding molecules
GB201906118D0 (en) Anti-LAG-3 binding molecules
GB202315963D0 (en) Binding molecules
GB202314107D0 (en) Binding molecules
GB202312621D0 (en) Binding molecules
GB202311267D0 (en) Binding molecules
GB202306345D0 (en) Binding molecules
GB202209573D0 (en) Binding molecules
EP3941947A4 (en) Anti-her2 binding molecules
GB202110360D0 (en) Binding molecules
GB202100737D0 (en) Binding molecules
GB202016611D0 (en) Binding molecules